

## Forest Laboratories

[View the current Forest Laboratories Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/4182-Forest+Laboratories.html)

(<http://www.bioportfolio.com/biocorporate/4182-Forest+Laboratories.html>)

### Contact Details:

909 Third Avenue

New York

NY

10022-4731

United States of America

Tel: 212 421 7850

Fax:

Email: [InvestorRelations@frx.com](mailto:InvestorRelations@frx.com)

Forest Laboratories develops, manufactures and sells both branded and generic forms of ethical products which require a physician's prescription, as well as non-prescription pharmaceutical products sold over-the-counter, which are used for the treatment of a wide range of illnesses.

Forest products are marketed principally in the United States and western and eastern Europe. Marketing is conducted by Forest and through independent distributors.

In the United States, Forest's ethical specialty products are marketed directly by the Company's Forest Pharmaceuticals, Forest Therapeutics, and Forest Specialty Sales salesforces. The Company's generic products are marketed directly by its Inwood Laboratories, Inc. subsidiary.

In the United Kingdom, Ireland and certain export markets, Forest products are marketed directly by the Company's subsidiaries, Pharmax Limited and the Tosara Group. Pharmax is a U.K. manufacturer and marketer of a range of specialty pharmaceuticals, including products manufactured by Forest and Tosara.

### Recent Publications by Forest Laboratories:



- [Effect of position isomerism on the formation and physicochemical properties of pharmaceutical co-crystals.](#)  
*The effect of position isomerism on the co-crystals formation and...*9th June, 2009  
Forest Laboratories, Inc., 49 Mall Drive, Commack, New York 11725.- J Pharm Sci. 2009 Jun 5. ([DOI](#) [Direct Link](#))
- [Modified-release solid formulations for colonic delivery.](#)  
*Solid formulations intended for targeted drug release into the lower...*27th March, 2009  
Department of Formulation, Pharmaceutical Research & Development, Forest- Recent Pat Drug Deliv Formul. 2007;1(1):53-63.
- [Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized](#)

[anxiety disorder.](#)

*Generalized anxiety disorder (GAD) is a highly prevalent and disabling...* 28th February, 2009  
Forest Laboratories, Harborside Financial Center, Jersey City, New Jersey,- *Depress Anxiety.*  
2008;25(10):854-61. ([DOI Direct Link](#))

- [Drug Safety and Pharmacovigilance--second annual marcus evans conference.](#)  
*Generalized anxiety disorder (GAD) is a highly prevalent and disabling...* 11th July, 2007  
Forest Laboratories UK Ltd, Bourne Road, Bexley, Kent, DA5 1NX, UK.- *IDrugs.* 2007 Mar;10(3):165-8.
- [Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.](#)  
*Cancer chemotherapeutic prodrugs, such as the oxazaphosphorines...* 28th April, 2006  
Forest Research Institute, A Division of Forest Laboratories, Inc.,- *Toxicol In Vitro.* 2006 Mar;20(2):176-86. Epub 2005 Nov 15. ([DOI Direct Link](#))
- [Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study.](#)  
*BACKGROUND: The high prevalence rates of both Alzheimer's disease (AD) and...* 2nd February, 2006  
Forest Research Institute, Forest Laboratories, Inc., Jersey City, New- *Clin Ther.* 2005 Oct;27(10):1596-606. ([DOI Direct Link](#))
- [Effects of formulation variables and characterization of guaifenesin wax microspheres for controlled release.](#)  
*Sustained-release wax microspheres of guaifenesin, a highly water-soluble...* 15th July, 2005  
Forest Laboratories Inc, Commack, New York, USA.- *Pharm Dev Technol.* 2005;10(1):71-83. ([DOI Direct Link](#))
- [Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.](#)  
*BACKGROUND: As part of ongoing studies to evaluate the analgesic efficacy...* 29th April, 2005  
Pharmacokinetic Properties Department, Forest Laboratories Inc.,- *Clin Ther.* 2004 Dec;26(12):2015-25. ([DOI Direct Link](#))
- [Stable amorphous danazol nanostructured powders with rapid dissolution rates produced by spray freezing into liquid.](#)  
*The objective of this study was to produce, by spray freezing into liquid...* 7th January, 2005  
Pharmaceutical Research and Development, Forest Laboratories, Inc.,- *Drug Dev Ind Pharm.* 2004 Aug;30(7):695-704. ([DOI Direct Link](#))
- [Microencapsulation of a hydrophilic drug into a hydrophobic matrix using a salting-out procedure. I: Development and optimization of the process using factorial design.](#)  
*The congealable disperse phase method for preparing sustained release...* 15th September, 2004  
Forest Laboratories, Inc., 330 Propsect Street, Inwood, NY 11096, USA.- *J Microencapsul.* 2004 Mar;21(2):125-35. ([DOI Direct Link](#))
- [Pharmacokinetic evaluation of 3'-azido-2', 3'-dideoxyuridine-5'-O-valinate-hydrochloride as a prodrug of the anti-HIV nucleoside 3'-azido-2', 3'-dideoxyuridine.](#)  
*3'-Azido-2', 3'-dideoxyuridine (AZDU, AzddU, CS-87) has been shown to have...* 31st August, 2004  
Forest Laboratories, Inc., Jersey City, NJ, USA.- *Antivir Chem Chemother.* 2003 Sep;14(5):263-70.
- [Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs.](#)  
*Poor water solubility is an industry wide issue, especially for...* 10th July, 2004  
Pharmaceutical Research and Development, Forest Laboratories, Inc.,- *Drug Dev Ind Pharm.* 2004 Mar;30(3):233-45. ([DOI Direct Link](#))
- [An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir.](#)  
*BACKGROUND: Depression often coexists with a number of disease states, and...* 30th August, 2003  
Forest Laboratories, Inc., New York, New York, USA.- *Clin Ther.* 2003 Apr;25(4):1200-10.
- [Multiple-dose proportionality study of flunisolide hydrofluoroalkane.](#)  
*The hydrofluoroalkane (HFA) formulation of the inhaled corticosteroid...* 13th March, 2003  
Department of Pharmacokinetics, Forest Laboratories, Inc., Harborside- *Allergy Asthma Proc.* 2002 Sep-Oct;23(5):311-8.

## Press Releases on Forest Laboratories:

[Reportlinker Adds  
Cell/Tissue Culture  
Supplies - A Global  
Market Perspective](#)

25th November,  
2009

Reportlinker

NEW YORK, Nov. 25 /PRNewswire/  
-- Reportlinker.com announces that a  
new market research report is  
available in its catalogue: Cell/Tissue  
Culture Supplies - A Global Market  
Perspective <http://www>

[Reportlinker Adds  
Laboratory Filtration  
Equipment - Global  
Market Trends](#)

25th November,  
2009

Reportlinker

NEW YORK, Nov. 25 /PRNewswire/  
-- Reportlinker.com announces that a  
new market research report is  
available in its catalogue: Laboratory  
Filtration Equipment - Global Market  
Trends <http://www>

[Reportlinker Adds  
Wound Care Products -  
A World Market  
Analysis](#)

25th November,  
2009

Reportlinker

NEW YORK, Nov. 25 /PRNewswire/  
-- Reportlinker.com announces that a  
new market research report is  
available in its catalogue: Wound  
Care Products - A World Market  
Analysis <http://www.reportlinker.com>

[Reportlinker Adds  
Intranasal Drug  
Delivery - US Market  
Trends & Analysis](#)

25th November,  
2009

Reportlinker

NEW YORK, Nov. 25 /PRNewswire/  
-- Reportlinker.com announces that a  
new market research report is  
available in its catalogue: Intranasal  
Drug Delivery - US Market Trends &  
Analysis <http://www>

[Reportlinker Adds  
Probiotics - A Global  
Update of Market  
Trends & Opportunities](#)

25th November,  
2009

Reportlinker

NEW YORK, Nov. 25 /PRNewswire/  
-- Reportlinker.com announces that a  
new market research report is  
available in its catalogue: Probiotics -  
A Global Update of Market Trends &  
Opportunities <http://>

## BioNews Results for Forest Laboratories



- [Global market for anti-depressants on a decline](#)  
*News-Medical.Net: Nov 20 2009 11:09AM Matching: forest laboratories*
- [Research and Markets: Central Nervous System Therapeutics - A Comprehensive World Market Review of Geographic](#)  
*RBC Dain Rauscher: Nov 19 2009 4:52PM Matching: forest laboratories*
- [Research and Markets: Central Nervous System Therapeutics - A Comprehensive World Market Review of Geographic](#)  
*Business Wire via Yahoo!: Nov 19 2009 4:50PM Matching: forest laboratories*
- [Research and Markets: Central Nervous System Therapeutics - A Comprehensive World Market Review of Geographic Coverage and Vertical Market Analysis](#)  
*Street Insider: Nov 19 2009 4:42PM Matching: forest laboratories*

- [Research and Markets: Central Nervous System Therapeutics - A Comprehensive World Market Review of Geographic](#)  
*Business Wire: Nov 19 2009 4:41PM Matching: forest laboratories*
- [Research and Markets: Central Nervous System Therapeutics - A Comprehensive World Market Review of Geographic Coverage and Vertical Market Analysis](#)  
*Business Wire UK: Nov 19 2009 4:35PM Matching: forest laboratories*
- [4-Star Stocks Poised to Pop: Alkermes](#)  
*The Money Times: Nov 18 2009 12:48PM Matching: forest laboratories*
- [Icahn Reports New Stakes In Genzyme, Forest Labs](#)  
*Wall Street Journal Online: Nov 17 2009 2:10PM Matching: forest laboratories*
- [Icahn Reports New Stakes In Genzyme, Forest Labs At Sept 30](#)  
*Morningstar.com: Nov 17 2009 12:19AM Matching: forest laboratories*
- [Icahn Reports New Stakes In Genzyme, Forest Labs At Sept 30](#)  
*Nasdaq: Nov 17 2009 12:17AM Matching: forest laboratories*
- [Icahn Reports New Stakes In Genzyme, Forest Labs At Sept 30](#)  
*CNN Money: Nov 17 2009 12:12AM Matching: forest laboratories*
- [Icahn Reports New Stakes In Genzyme, Forest Labs At Sept 30](#)  
*Wall Street Journal Online: Nov 17 2009 12:23AM Matching: forest laboratories*
- [BRIEF-Icahn Capital LP takes share stakes in Genzyme, Forest Labs](#)  
*Interactive Investor International: Nov 16 2009 11:44PM Matching: forest laboratories*
- [4-Star Stocks Poised to Pop: Alkermes](#)  
*Motley Fool via MSN Money: Nov 17 2009 2:46PM Matching: forest laboratories*
- [4-Star Stocks Poised to Pop: Alkermes](#)  
*Motley Fool: Nov 17 2009 2:37PM Matching: forest laboratories*

#### Forest Laboratories Clinical Trials:



- [Study to Evaluate Symptoms in Patients Treated With Nebivolol or Metoprolol Extended-Release \(ER\) for Hypertension](#)

#### Forest Laboratories Patents:



- 7569605- [Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion](#)
- 4357469- [Carrier base material for prolonged release therapeutic compositions](#)
- 4369172- [Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose](#)
- 4389393- [Sustained release therapeutic compositions based on high molecular weight](#)

- [hydroxypropylmethylcellulose](#)
- 4482534- [Nitroglycerin preparations](#)
- 4533540- [Nitroglycerin-containing polymeric matrix for sustained release on topical application](#)
- 4540566- [Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose](#)
- 4795327- [Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants](#)
- 4849229- [Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants](#)
- 4983398- [Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates](#)
- 5527822- [Method of treatment of traumatic brain injury](#)
- 7456224- [Method for treating autism](#)
- 7501438- [Pyridoimidazole derivatives](#)
- 7511150- [Synthesis of heterocyclic compounds](#)
- 7563797- [Substituted imidazo\(1,2-A\)pyrimidines and imidazo\(1,2-A\) pyridines as cannabinoid receptor ligands](#)
- 4226849- [Sustained release therapeutic compositions](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

